When should the pathologist request immunostaining with β-catenin?: A review of the literature on two cases

When should the pathologist request immunostaining with β-catenin?: A review of the literature on two cases

Main Article Content

Juvenal A. Ríos Leal
Laura Carreño
Claudia Morales
Iván Gallegos Méndez


For more than 20 years, immunohistochemistry has represented an auxiliary test of great relevance to support pathological work, however, it should be noted that the pillar of diagnosis continues and will continue to be the classic morphological description based on hematoxylin eosin and the trained eye of the specialist. In neoplastic pathologies, whether benign or malignant, it is becoming increasingly necessary to incorporate new tissue biomarkers that help objectify or confirm the diagnosis of each patient, in order to provide better treatment or a more precise diagnosis about the biological nature of their illness. In this line, there has been intense research in relation to the participation of the Wnt/β-catenin pathway in the development of various types of tumors, including colon adenocarcinoma, some pancreatic neoplasms and even some tumors of mesenchymal origin, as will be seen. in this work. In this context and based on two clinical cases of special interest, we have prepared a brief review of the literature considering the biological aspects of β-catenin, tumors where there is currently a true relative consensus that its immunolabeling offers a real contribution to the confirmation of the entity and finally a limited exposition regarding the future of this biomarker in the pathology discipline.


Bioulac-Sage, P., Cubel, G., Taouji, S., Scoazec, J.Y., Leteurtre, E., Paradis, V., Sturm, N., Nhieu, J.T. van, Wendum, D., Bancel, B., Ramos, J., Paraf, F., saint Paul, M.C., Michalak, S., Fabre, M., Guettier, C., le Bail, B., Zucman-Rossi, J., Balabaud, C., 2012. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol 36, 1691–1699.

BlueBooksOnline [WWW Document], n.d. URL https://tumourclassification.iarc.who.int/chaptercontent/33/40 (accessed 7.19.22a).

BlueBooksOnline [WWW Document], n.d. URL https://tumourclassification.iarc.who.int/chaptercontent/31/128 (accessed 7.19.22b).

Carlson, J.W., M Fletcher, C.D., W, C.J., D M, F.C., 2007. Immunohistochemistry for β-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology 51, 509–514.

Chagas, V.L., Rosman, F.C., da Costa Carvalho, M. da G., 2020. Solid pseudopapillary neoplasia of the pancreas: a review. Rev Assoc Med Bras 66, 87–94.

Fagotto, F., 2013. Looking beyond the Wnt pathway for the deep nature of β-catenin. EMBO Rep 14, 422–433.

Godoy, J.A., Rios, J.A., Zolezzi, J.M., Braidy, N., Inestrosa, N.C., 2014. Signaling pathway cross talk in Alzheimer’s disease. Cell Communication and Signaling 12.

Ishigaki, K., Namba, H., Nakashima, M., Nakayama, T., Mitsutake, N., Hayashi, T., Maeda, S., Ichinose, M., Kanematsu, T., Yamashita, S., 2002. Aberrant Localization of β-Catenin Correlates with Overexpression of Its Target Gene in Human Papillary Thyroid Cancer. J Clin Endocrinol Metab 87, 3433–3440.

Jackstadt, R., Hodder, M.C., Sansom, O.J., 2020. WNT and β-Catenin in Cancer: Genes and Therapy. https://doi.org/10.1146/annurev-cancerbio-030419-033628 4, 177–196.

Jeong, W.J., Ro, E.J., Choi, K.Y., 2018. Interaction between Wnt/β-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of β-catenin and RAS by targeting the Wnt/β-catenin pathway. npj Precision Oncology 2018 2:1 2, 1–10.

Juraschka, K., Taylor, M.D., 2019. Medulloblastoma in the age of molecular subgroups: a review: JNSPG 75th Anniversary Invited Review Article. J Neurosurg Pediatr 24, 353–363.

Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., Yin, G., 2022. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduction and Targeted Therapy 2021 7:1 7, 1–23.

Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins, C., Ng, H.K., Pfister, S.M., Reifenberger, G., Soffietti, R., von Deimling, A., Ellison, D.W., 2021.

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23, 1231–1251.

Mei, X., Su, H., Song, J., Dong, L., 2013. Prognostic significance of β-catenin expression in patients with non-small cell lung cancer: A meta-analysis. Biosci Trends 7, 42–49.

Moon, R.T., Gough, N.R., 2016. Beyond canonical: The Wnt and β-catenin story. Sci Signal 9, eg5–eg5. Nakatani, Y., Miyagi, Y., Takemura, T., Oka, T., Yokoi, T., Takagi, M., Yokoyama, S., Kashima, K., Hara, K., Yamada, T., Nozawa, A., Inayama, Y., Sakamoto, K., Ogawa, N., Kitamura, H., Resl, M., Cho, S.H., Koss, M.N., Mark, E.J., 2004. Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 28, 921–927.

Northcott, P.A., Robinson, G.W., Kratz, C.P., Mabbott, D.J., Pomeroy, S.L., Clifford, S.C., Rutkowski, S., Ellison, D.W., Malkin, D., Taylor, M.D., Gajjar, A., Pfister, S.M., 2019. Medulloblastoma. Nature Reviews Disease Primers 2019 5:1 5, 1–20.

Ríos, J.A., Cisternas, P., Arrese, M., Barja, S., Inestrosa, N.C., 2014. Is Alzheimer’s disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol 121.

Shang, S., Hua, F., Hu, Z.-W., Shang, S., Hua, F., Hu, Z.-W., 2017. The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget 8, 33972–33989.

Taank, Y., Agnihotri, N., 2021. Understanding the regulation of β-catenin expression and activity in colorectal cancer carcinogenesis: beyond destruction complex. Clinical and Translational Oncology 2021 23:12 23, 2448–2459.

Tsamis, I., Chachali, S.P., Gomatou, G., Trontzas, I., Mitsogianni, M., Syrigos, N., Vamvakaris, I., Kotteas, E., 2021. Pulmonary blastoma: a comprehensive overview of a rare entity. Adv Respir Med 89, 511–519.

Valenta, T., Hausmann, G., Basler, K., 2012. The many faces and functions of β-catenin. EMBO J 31, 2714–2736.

Wang, Z., Li, Z., Ji, H., 2021. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives. Med Res Rev 41, 2109–2129.

Wong, S.C.C., Lo, E.S.F., Lee, K.C., Chan, J.K.C., Hsiao, W.L.W., 2004. Prognostic and Diagnostic Significance of β-Catenin Nuclear Immunostaining in Colorectal Cancer. Clinical Cancer Research 10, 1401–1408.

Xie, X., Li, Y., Zhu, H., Kuang, Z., Chen, D., Fan, T., 2020. Prognostic significance of β-catenin expression in osteosarcoma: A meta-analysis. Front Oncol 10.

Yamada, Y., Hirata, M., Sakamoto, A., Noguchi, T., Ito, K., Nishida, Y., Matsuda, S., Haga, H., 2021. A comparison of the usefulness of nuclear beta-catenin in the diagnosis of desmoid-type fibromatosis among commonly used anti-beta-catenin antibodies. Pathol Int 71, 392–399.

Zeng, R., Duan, L., Kong, Y.K., Wu, X.L., Wang, Y., Xin, G., Yang, K.H., 2014. Prognostic significance of beta-catenin expression in patients with esophageal carcinoma: A meta-analysis. Asian Pacific Journal of Cancer Prevention 15, 6103–6108.

Zhan, T., Rindtorff, N., Boutros, M., 2017. Wnt signaling in cancer. Oncogene 36, 1461–1473.